John William Pepper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John William Pepper has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
Athena Aktipis
Arizona State University, Biodesign Institute, Tempe, AZ, USA
3 shared publicationsCarlo C. Maley
Molecular and Cellular Oncogenesis Program, The Wistar Institute Philadelphia, PA, USA
3 shared publications- Carlo C. Maley
Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University
3 shared publications David Sloan Wilson
Department of Biological Sciences, Binghamton University, Binghamton, NY
2 shared publications- Josh Mitteldorf
Institute for Frontier Experimental Science
2 shared publications Kathleen Sprouffske
Genomics and Computational Biology Program, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
2 shared publications
Latest Publications
- Open Access
- 8 August 2023
- Published by Springer Nature in Research Square
Integrated Analysis of Cancer Risk from Metabolic Dysfunction: Biological Mechanisms and Tipping Points
Obesity and metabolic syndrome are associated with the incidence of cancer, and they are rising epidemics. Therefore, clarification of the biological mechanisms of metabolic cancer risk is needed to guide strategies to intercept any elevated cancer risk resulting from metabolic syndrome. This study addressed whether interactions among known biological mechanisms elevate cancer risk, and which mechanisms offer the best leverage points for preventing any resulting cancer risk. It used a systems approach to examine the network of biological mechanisms, with special attention to clinically important feedbacks and tipping points. The results show that while no single mechanism leads from metabolic dysfunction to cancer risk, the integrated network of known mechanisms does. Metabolic syndrome collectively, and most of its components individually, induce documented oncogenic pathways. A network of such pathways leads from metabolic dysfunction to oncogenesis. This network includes self-reinforcing feedback loops, mostly centered on systemic metabolic inflammation, that can create tipping points into chronically dysfunctional metabolism with elevated cancer risk. Optimal interventions to reduce cancer risk should preempt these tipping points by targeting elements of metabolic dysfunction upstream of known feedback loops.
- 8 August 2023
- Published by Springer Nature in Research Square
Open AccessIntegrated Analysis of Cancer Risk from Metabolic Dysfunction: Biological Mechanisms and Tipping Points
Obesity and metabolic syndrome are associated with the incidence of cancer, and they are rising epidemics. Therefore, clarification of the biological mechanisms of metabolic cancer risk is needed to guide strategies to intercept any elevated cancer risk resulting from metabolic syndrome. This study addressed whether interactions among known biological mechanisms elevate cancer risk, and which mechanisms offer the best leverage points for preventing any resulting cancer risk. It used a systems approach to examine the network of biological mechanisms, with special attention to clinically important feedbacks and tipping points. The results show that while no single mechanism leads from metabolic dysfunction to cancer risk, the integrated network of known mechanisms does. Metabolic syndrome collectively, and most of its components individually, induce documented oncogenic pathways. A network of such pathways leads from metabolic dysfunction to oncogenesis. This network includes self-reinforcing feedback loops, mostly centered on systemic metabolic inflammation, that can create tipping points into chronically dysfunctional metabolism with elevated cancer risk. Optimal interventions to reduce cancer risk should preempt these tipping points by targeting elements of metabolic dysfunction upstream of known feedback loops.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
Supplementary Materials from Accurate Reconstruction of the Temporal Order of Mutations in Neoplastic Progression
- Open Access
- 1 January 2019
- Published by Oxford University Press (OUP) in Evolution, Medicine, and Public Health
- Vol. 2019 (1) , 9-16
Energy oversupply to tissues: a single mechanism possibly underlying multiple cancer risk factors
Background and objectives: Several major risk factors for cancer involve vascular oversupply of energy to affected tissues. These include obesity, diabetes and chronic inflammation. Here, we propose a potential mechanistic explanation for the association between energy oversupply and cancer risk, which we call the metabolic cancer suppression hypothesis: We hypothesize that oncogenesis is normally suppressed by organismal physiology that regulates and strictly limits normal energy supply to somatic cells, and that this protection is removed by abnormal oversupply of energy.Methodology: We evaluate this hypothesis using a computational model of somatic cell evolution to simulate experimental manipulation of the vascular energy supply to a tissue. The model simulates the evolutionary dynamics of somatic cells during oncogenesis.Results: In our simulation experiment, we found that under plausible biological assumptions, elevated energy supply to a tissue led to the evolution of elevated energy uptake by somatic cells, leading to the rapid evolution of both defining traits of cancer cells: hyperproliferation, and tissue invasion.Conclusions and implications: Our results support the hypothesis of metabolic cancer suppression, suggesting that vascular oversupply of energetic resources to somatic cells removes normal energetic limitations on cell proliferation, and that this accelerates cellular evolution toward cancer. Various predictions of this hypothesis are amenable to empirical testing, and have promising implications for translational research toward clinical cancer prevention.
- 1 January 2019
- Published by Oxford University Press (OUP) in Evolution, Medicine, and Public Health
- Vol. 2019 (1) , 9-16
Open AccessEnergy oversupply to tissues: a single mechanism possibly underlying multiple cancer risk factors
Background and objectives: Several major risk factors for cancer involve vascular oversupply of energy to affected tissues. These include obesity, diabetes and chronic inflammation. Here, we propose a potential mechanistic explanation for the association between energy oversupply and cancer risk, which we call the metabolic cancer suppression hypothesis: We hypothesize that oncogenesis is normally suppressed by organismal physiology that regulates and strictly limits normal energy supply to somatic cells, and that this protection is removed by abnormal oversupply of energy.Methodology: We evaluate this hypothesis using a computational model of somatic cell evolution to simulate experimental manipulation of the vascular energy supply to a tissue. The model simulates the evolutionary dynamics of somatic cells during oncogenesis.Results: In our simulation experiment, we found that under plausible biological assumptions, elevated energy supply to a tissue led to the evolution of elevated energy uptake by somatic cells, leading to the rapid evolution of both defining traits of cancer cells: hyperproliferation, and tissue invasion.Conclusions and implications: Our results support the hypothesis of metabolic cancer suppression, suggesting that vascular oversupply of energetic resources to somatic cells removes normal energetic limitations on cell proliferation, and that this accelerates cellular evolution toward cancer. Various predictions of this hypothesis are amenable to empirical testing, and have promising implications for translational research toward clinical cancer prevention.
- Open Access
- 21 October 2016
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 7 (2) , a029652
Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks
Evolution by natural selection is the conceptual foundation for nearly every branch of biology and increasingly also for biomedicine and medical research. In cancer biology, evolution explains how populations of cells in tumors change over time. It is a fundamental question whether this evolutionary process is driven primarily by natural selection and adaptation or by other evolutionary processes such as founder effects and drift. In cancer biology, as in organismal evolutionary biology, there is controversy about this question and also about the use of adaptation through natural selection as a guiding framework for research. In this review, we discuss the differences and similarities between evolution among somatic cells versus evolution among organisms. We review what is known about the parameters and rate of evolution in neoplasms, as well as evidence for adaptation. We conclude that adaptation is a useful framework that accurately explains the defining characteristics of cancer. Further, convergent evolution through natural selection provides the only satisfying explanation both for how a group of diverse pathologies have enough in common to usefully share the descriptive label of “cancer” and for why this convergent condition becomes life-threatening.
- 21 October 2016
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 7 (2) , a029652
Open AccessNatural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks
Evolution by natural selection is the conceptual foundation for nearly every branch of biology and increasingly also for biomedicine and medical research. In cancer biology, evolution explains how populations of cells in tumors change over time. It is a fundamental question whether this evolutionary process is driven primarily by natural selection and adaptation or by other evolutionary processes such as founder effects and drift. In cancer biology, as in organismal evolutionary biology, there is controversy about this question and also about the use of adaptation through natural selection as a guiding framework for research. In this review, we discuss the differences and similarities between evolution among somatic cells versus evolution among organisms. We review what is known about the parameters and rate of evolution in neoplasms, as well as evidence for adaptation. We conclude that adaptation is a useful framework that accurately explains the defining characteristics of cancer. Further, convergent evolution through natural selection provides the only satisfying explanation both for how a group of diverse pathologies have enough in common to usefully share the descriptive label of “cancer” and for why this convergent condition becomes life-threatening.
- 14 May 2016
- Published by Springer Nature
- p. 167-175
Darwinian Strategies to Avoid the Evolution of Drug Resistance During Cancer Treatment
- 14 May 2016
- Published by Springer Nature
- p. 167-175
Darwinian Strategies to Avoid the Evolution of Drug Resistance During Cancer Treatment
- Open Access
- 27 February 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep08645
In North America, Some Ovarian Cancers Express the Oncogenes of Preventable Human Papillomavirus HPV-18
Some researchers in other regions have recommended human papillomavirus (HPV) vaccination to reduce risk of ovarian cancer, but not in North America, where evidence has previously suggested no role for HPV in ovarian cancer. Here we use a large sample of ovarian cancer transcriptomes (RNA-Seq) from The Cancer Genome Atlas (TCGA) database to address whether HPV is involved with ovarian cancer in North America. We estimate that a known high-risk type of HPV (type 18) is present and active in 1.5% of cases of ovarian epithelial cancers in the US and Canada. Our detection methods were verified by negative and positive controls and our sequence matches indicated high validity, leading to strong confidence in our conclusions. Our results indicate that previous reports of zero prevalence of HPV in North American cases of ovarian cancer should not be considered conclusive. This is important because currently used vaccines protect against the HPV-18 that is active in ovarian tumors and, therefore, may reduce risk in North America of cancers of the ovaries as well as of the cervix and several other organ sites.
- 27 February 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep08645
Open AccessIn North America, Some Ovarian Cancers Express the Oncogenes of Preventable Human Papillomavirus HPV-18
Some researchers in other regions have recommended human papillomavirus (HPV) vaccination to reduce risk of ovarian cancer, but not in North America, where evidence has previously suggested no role for HPV in ovarian cancer. Here we use a large sample of ovarian cancer transcriptomes (RNA-Seq) from The Cancer Genome Atlas (TCGA) database to address whether HPV is involved with ovarian cancer in North America. We estimate that a known high-risk type of HPV (type 18) is present and active in 1.5% of cases of ovarian epithelial cancers in the US and Canada. Our detection methods were verified by negative and positive controls and our sequence matches indicated high validity, leading to strong confidence in our conclusions. Our results indicate that previous reports of zero prevalence of HPV in North American cases of ovarian cancer should not be considered conclusive. This is important because currently used vaccines protect against the HPV-18 that is active in ovarian tumors and, therefore, may reduce risk in North America of cancers of the ovaries as well as of the cervix and several other organ sites.
- Open Access
- 1 January 2014
- Published by Oxford University Press (OUP) in Evolution, Medicine, and Public Health
- Vol. 2014 (1) , 65-68
The evolution of bacterial social life: From the ivory tower to the front lines of public health
Drug-resistant bacteria are a huge and growing threat to public health. A solution exists in theory, but had not yet been put to a practical test. The accompanying paper by Ross-Gillespie et al., the theory is put to a test and performs successfully. As predicted, using a drug that targets bacteria's shared secreted ‘public goods’ molecules instead of cell components did not drive the bacterial evolution of drug resistance, and therefore retained its effectiveness. This result holds great promise for better drugs and vaccines against many infectious diseases, and also for better cancer therapies.
- 1 January 2014
- Published by Oxford University Press (OUP) in Evolution, Medicine, and Public Health
- Vol. 2014 (1) , 65-68
Open AccessThe evolution of bacterial social life: From the ivory tower to the front lines of public health
Drug-resistant bacteria are a huge and growing threat to public health. A solution exists in theory, but had not yet been put to a practical test. The accompanying paper by Ross-Gillespie et al., the theory is put to a test and performs successfully. As predicted, using a drug that targets bacteria's shared secreted ‘public goods’ molecules instead of cell components did not drive the bacterial evolution of drug resistance, and therefore retained its effectiveness. This result holds great promise for better drugs and vaccines against many infectious diseases, and also for better cancer therapies.
- 1 January 2014
- Published by Ashdin Publishing in Journal of Evolutionary Medicine
- Vol. 2, 1-8
Using Systems Biology to Understand Cancer as an Evolutionary Process
- 1 January 2014
- Published by Ashdin Publishing in Journal of Evolutionary Medicine
- Vol. 2, 1-8
Using Systems Biology to Understand Cancer as an Evolutionary Process
- 31 July 2012
- Published by Elsevier in Trends in Ecology & Evolution
- Vol. 27 (7) , 381-384
The emerging medical ecology of the human gut microbiome
- 31 July 2012
- Published by Elsevier in Trends in Ecology & Evolution
- Vol. 27 (7) , 381-384
The emerging medical ecology of the human gut microbiome